AIM: Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients' susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity. PATIENTS & METHODS: Genotyping was performed in 64 pediatric patients and significant findings were re-evaluated in 66 adults. RESULTS: The SLC22A2 polymorphism rs316019 (c.808G>T; Ser270Ala) was significantly associated with protection from cisplatin-induced ototoxicity in the pediatric (p = 0.022) and the adult cohort (p = 0.048; both: Fisher's exact test). This result was confirmed by multiple logistic regression analysis accounting for age which was identified as a relevant factor for ototoxicity as well (rs316019: OR [G/T vs G/G] = 0.12, p = 0.009; age: OR [per year]: 0.84, p = 0.02). CONCLUSION: These results identified rs316019 as potential pharmacogenomic marker for cisplatin-induced ototoxicity and point to a critical role of SLC22A2 for cisplatin transport in humans and its contribution to the organ specific side effects of this drug. Original submitted 17 September 2014; Revision submitted 19 December 2014.
AIM: Assuming that genetic variants of the SLC22A2 and SLC31A1 transporter affect patients' susceptibility to cisplatin-induced ototoxicity, we compared the distribution of 11 SLC22A2 variants and the SLC31A1 variant rs10981694 between patients with and without cisplatin-induced ototoxicity. PATIENTS & METHODS: Genotyping was performed in 64 pediatric patients and significant findings were re-evaluated in 66 adults. RESULTS: The SLC22A2 polymorphism rs316019 (c.808G>T; Ser270Ala) was significantly associated with protection from cisplatin-induced ototoxicity in the pediatric (p = 0.022) and the adult cohort (p = 0.048; both: Fisher's exact test). This result was confirmed by multiple logistic regression analysis accounting for age which was identified as a relevant factor for ototoxicity as well (rs316019: OR [G/T vs G/G] = 0.12, p = 0.009; age: OR [per year]: 0.84, p = 0.02). CONCLUSION: These results identified rs316019 as potential pharmacogenomic marker for cisplatin-induced ototoxicity and point to a critical role of SLC22A2 for cisplatin transport in humans and its contribution to the organ specific side effects of this drug. Original submitted 17 September 2014; Revision submitted 19 December 2014.
Authors: Allison Yancey; Michael S Harris; Akinbode Egbelakin; Jaimie Gilbert; David B Pisoni; Jamie Renbarger Journal: Pediatr Blood Cancer Date: 2012-03-19 Impact factor: 3.167
Authors: Swati S More; Omar Akil; Alexandra G Ianculescu; Ethan G Geier; Lawrence R Lustig; Kathleen M Giacomini Journal: J Neurosci Date: 2010-07-14 Impact factor: 6.167
Authors: L Riedemann; C Lanvers; D Deuster; U Peters; J Boos; H Jürgens; A am Zehnhoff-Dinnesen Journal: Pharmacogenomics J Date: 2007-04-24 Impact factor: 3.550
Authors: Matthew J Lewis; Steven G DuBois; Brian Fligor; Xiaochun Li; Allen Goorin; Holcombe E Grier Journal: Pediatr Blood Cancer Date: 2009-03 Impact factor: 3.167
Authors: Charlotte L Zuur; Yvonne J Simis; Pauline E Lansdaal; Augustinus A Hart; Coen R Rasch; Jan H Schornagel; Wouter A Dreschler; Alfons J Balm Journal: Int J Radiat Oncol Biol Phys Date: 2007-04-06 Impact factor: 7.038
Authors: Heather E Wheeler; Eric R Gamazon; Robert D Frisina; Carlos Perez-Cervantes; Omar El Charif; Brandon Mapes; Sophie D Fossa; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair J Beard; Chunkit Fung; Christian Kollmannsberger; Jeri Kim; Taisei Mushiroda; Michiaki Kubo; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Nancy J Cox; M Eileen Dolan; Lois B Travis Journal: Clin Cancer Res Date: 2016-12-30 Impact factor: 12.531
Authors: Britt I Drögemöller; Jose G Monzon; Amit P Bhavsar; Adrienne E Borrie; Beth Brooks; Galen E B Wright; Geoffrey Liu; Daniel J Renouf; Christian K Kollmannsberger; Philippe L Bedard; Folefac Aminkeng; Ursula Amstutz; Claudette A Hildebrand; Erandika P Gunaretnam; Carol Critchley; Zhuo Chen; Liam R Brunham; Michael R Hayden; Colin J D Ross; Karen A Gelmon; Bruce C Carleton Journal: JAMA Oncol Date: 2017-11-01 Impact factor: 31.777
Authors: Kevin M Huang; Muhammad Erfan Uddin; Duncan DiGiacomo; Maryam B Lustberg; Shuiying Hu; Alex Sparreboom Journal: Expert Opin Drug Metab Toxicol Date: 2020-04-26 Impact factor: 4.481
Authors: Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu Journal: Rev Physiol Biochem Pharmacol Date: 2022 Impact factor: 7.500